dactinomycin has been researched along with fenofibrate in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (28.57) | 29.6817 |
2010's | 5 (71.43) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Fujii, S; Furumoto, T; Goto, D; Ishimori, N; Kaneko, T; Kitabatake, A; Matsumoto, A; Sobel, BE; Sugawara, T; Watano, K | 1 |
Goya, K; Kasayama, S; Kawase, I; Kitamura, T; Kouhara, H; Kurebayashi, S; Saito, H; Sumitani, S; Xu, X; Yamamoto, H | 1 |
1 review(s) available for dactinomycin and fenofibrate
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for dactinomycin and fenofibrate
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Induction of plasminogen activator inhibitor-1 in endothelial cells by basic fibroblast growth factor and its modulation by fibric acid.
Topics: 5' Flanking Region; Anticholesteremic Agents; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line; Dactinomycin; DNA; Endothelium, Vascular; Enzyme Inhibitors; Fenofibrate; Fibroblast Growth Factor 2; Flavonoids; Humans; Plasminogen Activator Inhibitor 1; Protein Synthesis Inhibitors; RNA, Messenger; Transcription, Genetic; Umbilical Veins | 2002 |
Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells.
Topics: Animals; Aorta; Bezafibrate; Cattle; Cells, Cultured; Dactinomycin; Endothelial Cells; Endothelium, Vascular; Enzyme Induction; Fenofibrate; Gene Expression Regulation, Enzymologic; Half-Life; Mifepristone; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pyrimidines; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transfection | 2004 |